Close Menu

NEW YORK – Immunotherapy developer Advaxis and sequencing firm Personalis said today that they have entered an extended collaboration agreement, under which they are using Personalis' ImmunoID NeXT Platform for biomarker discovery in Advaxis' ongoing Phase I/II program advancing the investigational ADXS-503 alone and in combination with pembrolizumab for patients with non-small cell lung cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.